Abstract
The aim of this paper is to show - from the historical overview over theoretical knowledge - today the possibility of clinical use C-peptide. The benefit may be its determination for the classification of diabetes, impaired glucose homeostasis, as well as for decision making the selection, strategy and timing of treatment and, most recently, based on new knowledge about the functions of endogenous C-peptide, is intensely studied the therapeutic-preventive use for modeling the development of vascular and neuropathic complications of diabetes.
The latter appointed to panel if the actual deployment may affect morbidity and mortality in diabetics.